tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Jami Rubin, 48 are a BUY (54.55%), 27 are a HOLD (30.68%), 13 are a SELL (14.77%).
Analyst Jami Rubin, carries an average stock price target met ratio of 77.63% that have a potential upside of 41% achieved within 820 days. Previously, Jami Rubin worked at MORGAN STANLEY, GOLDMAN SACHS.
Jami Rubin’s has documented 174 price targets and ratings displayed on 14 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on LLY, Eli Lilly and Company at 14-Oct-2018.
Analyst best performing recommendations are on ZTS (ZOETIS).
The best stock recommendation documented was for TEVA (TEVA PHARMA INDUSTRIES LTD ADR) at 12/15/2017. The price target of $20 was fulfilled within 26 days with a profit of $1.39 (7.47%) receiving and performance score of 2.87.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 17-Nov-2020
$338
$43.11 (14.62%)
$282
Buy Since 04-Feb-2020
$322
$27.11 (9.19%)
$288
Buy Since 07-Dec-2021
$340
$45.11 (15.30%)
$300
Buy Since 01-Nov-2026
$342
$47.11 (15.98%)
$206
Buy Since 05-Apr-2022
$346
$51.11 (17.33%)
$310
